Covid19-Sources

4433 bookmarks
Custom sorting
molecular.sylvia on Twitter
molecular.sylvia on Twitter
Was?? Es sind nicht die Long Lockdown Adeno-Dogs? *Shocked* https://t.co/X9bkkXr1b7SARS-CoV-2 ORF1abA1061S Mutation resultiert in einem PARP14 identen Peptid, das über HLA-A präsentiert wird und autoreaktive zytotoxische T-Zellen begünstigt.— molecular.sylvia (@SylviaGruber88) June 30, 2022
·twitter.com·
molecular.sylvia on Twitter
Eric Topol on Twitter
Eric Topol on Twitter
The Omicron BA.4/5 subvariants are leading to a new wave in Europe and the United States, with an impact of some increase in hospitalizationshttps://t.co/y0LvkzoCRb @SarahNev @JamieSmythF @jburnmurdoch @TWenseleers pic.twitter.com/pBuS7Xc5Li— Eric Topol (@EricTopol) June 17, 2022
·twitter.com·
Eric Topol on Twitter
Ralf Wittenbrink on Twitter
Ralf Wittenbrink on Twitter
Dies ist eine äußerst wichtige Studie, die darauf hindeutet, dass eine Infektion durch frühere Varianten die schützende Immunität gegen nachfolgende Varianten verändern und sogar beeinträchtigen kann – ein Prozess, der von den Autoren als „Hybrid-Immundämpfung“…#COVID19 pic.twitter.com/uBqYpwQiVI— Ralf Wittenbrink (@RWittenbrink) June 15, 2022
·twitter.com·
Ralf Wittenbrink on Twitter
Practical Indicators for Risk of Airborne Transmission in Shared Indoor Environments and Their Application to COVID-19 Outbreaks - acs.est.1c06531
Practical Indicators for Risk of Airborne Transmission in Shared Indoor Environments and Their Application to COVID-19 Outbreaks - acs.est.1c06531
Some infectious diseases, including COVID-19, can undergo airborne transmission. This may happen at close proximity, but as time indoors increases, infections can occur in shared room air despite distancing. We propose two indicators of infection risk for this situation, that is, relative risk parameter (Hr) and risk parameter (H). They combine the key factors that control airborne disease transmission indoors: virus- containing aerosol generation rate, breathing flow rate, masking and its quality, ventilation and aerosol-removal rates, number of occupants, and duration of exposure. COVID-19 outbreaks show a clear trend that is consistent with airborne infection and enable recommendations to minimize transmission risk. Transmission in typical prepandemic indoor spaces is highly sensitive to mitigation efforts. Previous outbreaks of measles, influenza, and tuberculosis were also assessed. Measles outbreaks occur at much lower risk parameter values than COVID-19, while tuberculosis outbreaks are observed at higher risk parameter values. Because both diseases are accepted as airborne, the fact that COVID-19 is less contagious than measles does not rule out airborne transmission. It is important that future outbreak reports include information on masking, ventilation and aerosol-removal rates, number of occupants, and duration of exposure, to investigate airborne transmission.
·pubs.acs.org·
Practical Indicators for Risk of Airborne Transmission in Shared Indoor Environments and Their Application to COVID-19 Outbreaks - acs.est.1c06531
Long COVID-19 Liver Manifestation in Children : Journal of Pediatric Gastroenterology and Nutrition
Long COVID-19 Liver Manifestation in Children : Journal of Pediatric Gastroenterology and Nutrition
pathy has been increasingly reported in adults. In children, data are sparse. Our aim was to describe pediatric patients who recovered from COVID-19 and later presented with liver injury. Methods: This is a retrospective case-series study of pediatric patients with post-COVID-19 liver manifestations. We collected data on demographics, medical history, clinical presentation, laboratory results, imaging, histology, treatment, and outcome. Results: We report five pediatric patients who recovered from COVID-19 and later presented with liver injury. Two types of clinical presentation were distinguishable. Two infants aged 3 and 5 months, previously healthy, presented with acute liver failure that rapidly progressed to liver transplantation. Their liver explant showed massive necrosis with cholangiolar proliferation and lymphocytic infiltrate. Three children, two aged 8 years and one aged 13 years, presented with hepatitis with cholestasis. Two children had a liver biopsy significant for lymphocytic portal and parenchyma inflammation, along with bile duct proliferations. All three were started on steroid treatment; liver enzymes improved, and they were weaned successfully from treatment. For all five patients, extensive etiology workup for infectious and metabolic etiologies were negative. Conclusions: We report two distinct patterns of potentially long COVID-19 liver manifestations in children with common clinical, radiological, and histopathological characteristics after a thorough workup excluded other known etiologies. Copyright © 2022 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...
·journals.lww.com·
Long COVID-19 Liver Manifestation in Children : Journal of Pediatric Gastroenterology and Nutrition
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
The Omicron, or Pango lineage B.1.1.529, variant of SARS-CoV-2 carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection from severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple mRNA vaccinated healthcare workers (HCW) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple vaccinated individuals, but magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCW who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants, but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.
·science.org·
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
Adam Kucharski on Twitter
Adam Kucharski on Twitter
Think you know flu? Read this fascinating study from @nicd_sa et al - with detailed sampling, estimated over 40% of population got infected per season on average, and 17% had repeat infection within same season. Also evidence of asymptomatic transmission: https://t.co/pXIITwGYT8 pic.twitter.com/JOZyvzFqG7— Adam Kucharski (@adamjkucharski) May 19, 2021
·twitter.com·
Adam Kucharski on Twitter
Martin Sauter on Twitter
Martin Sauter on Twitter
In Australien wird mittlerweile über einen "plötzlichen Erwachsenentod" (SADS Sudden Adult Death Syndrome, analog zum plötzlichen Kindstod) berichtet. https://t.co/BOaQ3UTssK1/N— Martin Sauter (@Martin__Sauter) June 14, 2022
·twitter.com·
Martin Sauter on Twitter
Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years
Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years
An increase of acute hepatitis of unknown aetiology has been reported among children in multiple countries worldwide. With a rapid online survey among hospitals in and outside of Europe, we describe case numbers recorded from 1 January to 18 April 2022 vs the previous 5 years. Of 24 countries that responded, we identified 5/17 European and 1/7 non-European countries with an elevation in probable cases of unexplained acute hepatitis, and severe cases were elevated in five European countries.
·eurosurveillance.org·
Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years
Corona: Informationen, Schulschließungen und Tests wirken gegen Infektion
Corona: Informationen, Schulschließungen und Tests wirken gegen Infektion
Unter den sogenannten nicht-pharmazeutischen Maßnahmen zur Eindämmung der Corona-Pandemie waren öffentliche Informationskampagnen und Schulschließungen am effektivsten. Sie senkten die Reproduktionszahl, also die Anzahl an Menschen, die eine infizierte Person im Durchschnitt ansteckt, um 0,35 bzw. 0,24. Dies ist das Ergebnis einer Studie unter Beteiligung des IfW Kiel, die auch systematisch Daten außerhalb der USA und Chinas, unter anderem aus Deutschland, auswertete.
·ifw-kiel.de·
Corona: Informationen, Schulschließungen und Tests wirken gegen Infektion
Humoral and cellular immune memory to four COVID-19 vaccines
Humoral and cellular immune memory to four COVID-19 vaccines
Multiple COVID-19 vaccines, representing diverse vaccine platforms, successfully protect against symptomatic COVID-19 cases and deaths. Head-to-head comparisons of T cell, B cell, and antibody responses to diverse vaccines in humans are likely to be informative for understanding protective immunity against COVID-19, with particular interest in immune memory. Here, SARS-CoV-2-spike-specific immune responses to Moderna mRNA-1273, Pfizer/BioNTech BNT162b2, Janssen Ad26.COV2.S and Novavax NVX-CoV2373 were examined longitudinally for 6 months. 100% of individuals made memory CD4+ T cells, with cTfh and CD4-CTL highly represented after mRNA or NVX-CoV2373 vaccination. mRNA vaccines and Ad26.COV2.S induced comparable CD8+ T cell frequencies, though only detectable in 60-67% of subjects at 6 months. A differentiating feature of Ad26.COV2.S immunization was a high frequency of CXCR3+ memory B cells. mRNA vaccinees had substantial declines in antibodies, while memory T and B cells were comparatively stable. These results may also be relevant for insights against other pathogens.
·cell.com·
Humoral and cellular immune memory to four COVID-19 vaccines
Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection
Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection
Several studies show neutralizing antibody levels are an important correlate of immune protection from COVID-19 and have estimated the relationship between neutralizing antibodies and protection. However, a number of these studies appear to yield quite different estimates of the level of neutralizing antibodies required for protection. Here we show that after normalization of antibody titers current studies converge on a consistent relationship between antibody levels and protection from COVID-19. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work is supported by an Australian government Medical Research Future Fund awards GNT2002073 (to MPD, SJK, AKW), MRF2005544 (to SJK, AKW, JAJ and MPD), MRF2005760 (to MPD), MRF2007221 (to JAT and MS), an NHMRC program grant GNT1149990 (SJK and MPD), and the Victorian Government (SJK, AKW, JAJ). JAJ, DSK and SJK are supported by NHMRC fellowships. AKW, DC and MPD are supported by NHMRC Investigator grants. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. The funding source had no role in the writing of the manuscript or the decision to submit it for publication, nor in data collection, analysis, or interpretation; or any aspect pertinent to the study. Authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All data were publicly available and the raw data use was either extracted from publications (Feng et al. Nature Medicine 2021, Gilbert et al. Science 2021) or provided by the authors on request (Bergwerk et al. New England Journal of Medicine 2021). Analysis of this publicly available data was approved under the UNSW Sydney Human Research Ethics Committee (approval HC200242). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data and code will be made available on GitHub upon publication.
·medrxiv.org·
Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection
The Department of Immunization, Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible.
The Department of Immunization, Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible.
1WHO/IVB/13.01 The ability to assess the protective efficacy of a vaccine by measuring the proportion of vaccinees who generate a particular immune response, without having to measure clinical outcomes, has significant advantages. The availability and quality of such substitute endpoints1 are important for vaccine development, licensure and effectiveness monitoring. A better understanding of the interrelationships between vaccination, the immune response, protection, and clinical outcomes is thus of interest not only to regulatory authorities but also to microbiologists, immunologists, epidemiologists and statisticians. This is a complex and controversial topic, and many aspects need clarification. Although regulatory bodies have drawn up definitions for “correlates” and “surrogates” of protection for the purpose of licensure, these terms are not used consistently among regulators, nor in the broader literature. Different study designs, each with their strengths and weaknesses, have been used to evaluate immunological substitute endpoints of vaccine-induced protection. Various statistical tools have been developed to evaluate these endpoints, but few epidemiologists are familiar with the details of these methods. Immunological substitute endpoints can be relative or absolute quantities, and further information is needed on how they are affected by factors such as the challenge dose, the mechanism of action of the vaccine, the environment, or host characteristics. This document presents an overview of definitions and methods relating to studies of substitute endpoints. It aims to facilitate communication and to encourage the development of a broad research agenda on the issue. Although the greatest interest in this topic currently relates to vaccines, immunological correlates of protection have far-reaching implications for passive protection (maternal immunity and immunoglobulin prophylaxis), risk screening (e.g. tuberculin or rubella antibody testing in pregnant women) as well as for a basic understanding of pathogenesis and immunity.
·apps.who.int·
The Department of Immunization, Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible.
Correlates of Protection Induced by Vaccination
Correlates of Protection Induced by Vaccination
This paper attempts to summarize current knowledge about immune responses to vaccines that correlate with protection. Although the immune system is redundant, almost all current vaccines work through antibodies in serum or on mucosa that block infection or bacteremia/viremia and thus provide a correlate of protection. The functional characteristics of antibodies, as well as quantity, are important. Antibody may be highly correlated with protection or synergistic with other functions. Immune memory is a critical correlate: effector memory for short-incubation diseases and central memory for long-incubation diseases. Cellular immunity acts to kill or suppress intracellular pathogens and may also synergize with antibody. For some vaccines, we have no true correlates, but only useful surrogates, for an unknown protective response.
·journals.asm.org·
Correlates of Protection Induced by Vaccination